161 related articles for article (PubMed ID: 37665362)
1. Application of high throughput in vitro metabolomics for hepatotoxicity mode of action characterization and mechanistic-anchored point of departure derivation: a case study with nitrofurantoin.
Ramirez-Hincapie S; Birk B; Ternes P; Giri V; Zickgraf FM; Haake V; Herold M; Kamp H; Driemert P; Landsiedel R; Richling E; Funk-Weyer D; van Ravenzwaay B
Arch Toxicol; 2023 Nov; 97(11):2903-2917. PubMed ID: 37665362
[TBL] [Abstract][Full Text] [Related]
2. A high-throughput metabolomics in vitro platform for the characterization of hepatotoxicity.
Ramirez-Hincapie S; Birk B; Ternes P; Giri V; Haake V; Herold M; Zickgraf FM; Verlohner A; Huener HA; Kamp H; Driemert P; Landsiedel R; Richling E; Funk-Weyer D; van Ravenzwaay B
Cell Biol Toxicol; 2023 Dec; 39(6):2899-2917. PubMed ID: 37138123
[TBL] [Abstract][Full Text] [Related]
3. Derivation of metabolic point of departure using high-throughput in vitro metabolomics: investigating the importance of sampling time points on benchmark concentration values in the HepaRG cell line.
Malinowska JM; Palosaari T; Sund J; Carpi D; Weber RJM; Lloyd GR; Whelan M; Viant MR
Arch Toxicol; 2023 Mar; 97(3):721-735. PubMed ID: 36683062
[TBL] [Abstract][Full Text] [Related]
4. [A novel method for efficient screening and annotation of important pathway-associated metabolites based on the modified metabolome and probe molecules].
Li Z; Zheng F; Xia Y; Zhang X; Wang X; Zhao C; Zhao X; Lu X; Xu G
Se Pu; 2022 Sep; 40(9):788-796. PubMed ID: 36156625
[TBL] [Abstract][Full Text] [Related]
5. Metabonomic study on the antitumor effect of flavonoid derivative 3d in HepG2 cells and its action mechanism.
Gao D; Jin F; Liu H; Wang Y; Jiang Y
Talanta; 2014 Jan; 118():382-8. PubMed ID: 24274312
[TBL] [Abstract][Full Text] [Related]
6. In vitro assessment of hepatotoxicity by metabolomics: a review.
Cuykx M; Rodrigues RM; Laukens K; Vanhaecke T; Covaci A
Arch Toxicol; 2018 Oct; 92(10):3007-3029. PubMed ID: 30155722
[TBL] [Abstract][Full Text] [Related]
7. Integrated spatially resolved metabolomics and network toxicology to investigate the hepatotoxicity mechanisms of component D of Polygonum multiflorum Thunb.
Jiang HY; Gao HY; Li J; Zhou TY; Wang ST; Yang JB; Hao RR; Pang F; Wei F; Liu ZG; Kuang L; Ma SC; He JM; Jin HT
J Ethnopharmacol; 2022 Nov; 298():115630. PubMed ID: 35987407
[TBL] [Abstract][Full Text] [Related]
8. High-throughput metabolomics screen coupled with multivariate statistical analysis identifies therapeutic targets in alcoholic liver disease rats using liquid chromatography-mass spectrometry.
Fang H; Zhang AH; Sun H; Yu JB; Wang L; Wang XJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Mar; 1109():112-120. PubMed ID: 30743140
[TBL] [Abstract][Full Text] [Related]
9. The combination of four analytical methods to explore skeletal muscle metabolomics: Better coverage of metabolic pathways or a marketing argument?
Bruno C; Patin F; Bocca C; Nadal-Desbarats L; Bonnier F; Reynier P; Emond P; Vourc'h P; Joseph-Delafont K; Corcia P; Andres CR; Blasco H
J Pharm Biomed Anal; 2018 Jan; 148():273-279. PubMed ID: 29059617
[TBL] [Abstract][Full Text] [Related]
10. Modeling HepaRG metabolome responses to pyrrolizidine alkaloid exposure for insight into points of departure and modes of action.
Dubreil E; Darney K; Delignette-Muller ML; Barranger A; Huet S; Hogeveen K; Léger T; Fessard V; Hégarat LL
J Hazard Mater; 2024 Aug; 474():134721. PubMed ID: 38843629
[TBL] [Abstract][Full Text] [Related]
11. Metabolomics-based strategy to assess drug hepatotoxicity and uncover the mechanisms of hepatotoxicity involved.
Martínez-Sena T; Moro E; Moreno-Torres M; Quintás G; Hengstler J; Castell JV
Arch Toxicol; 2023 Jun; 97(6):1723-1738. PubMed ID: 37022445
[TBL] [Abstract][Full Text] [Related]
12. A large-scale analysis of targeted metabolomics data from heterogeneous biological samples provides insights into metabolite dynamics.
Lee HJ; Kremer DM; Sajjakulnukit P; Zhang L; Lyssiotis CA
Metabolomics; 2019 Jul; 15(7):103. PubMed ID: 31289941
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of metabolite differences in skin between Clapp's Favorite and its mutant Red Clapp's Favorite through non-targeted metabolomics].
Mu H; Ci Z; Aisajan M; Liang Y; Liu X; DU X; Yu Q; Li Q; Li Y
Se Pu; 2021 Nov; 39(11):1203-1212. PubMed ID: 34677015
[TBL] [Abstract][Full Text] [Related]
14. LC-MS untargeted metabolomics assesses the delayed response of glufosinate treatment of transgenic glufosinate resistant (GR) buffalo grasses (Stenotaphrum secundatum L.).
Boonchaisri S; Rochfort S; Stevenson T; Dias DA
Metabolomics; 2021 Feb; 17(3):28. PubMed ID: 33609206
[TBL] [Abstract][Full Text] [Related]
15. [Lipid metabolomic analysis in exosomes of osteonecrosis of the femoral head based on ultra performance liquid chromatography-tandem mass spectrometry].
Guo M; Zhang J
Se Pu; 2022 Feb; 40(2):123-129. PubMed ID: 35080158
[TBL] [Abstract][Full Text] [Related]
16. Qualitative and quantitative concentration-response modelling of gene co-expression networks to unlock hepatotoxic mechanisms for next generation chemical safety assessment.
Kunnen SJ; Arnesdotter E; Willenbockel CT; Vinken M; van de Water B
ALTEX; 2024; 41(2):213-232. PubMed ID: 38376873
[TBL] [Abstract][Full Text] [Related]
17. Targeted metabolomics analysis for serum Helicobacter pylori-positive based on liquid chromatography-tandem mass spectrometry.
Wang J; Shan J; Zhang Y; Shi Y; Lu D; Wu Y; Guo XP; Liu H; Wang J; Hu N
Biomed Chromatogr; 2023 Jun; 37(6):e5622. PubMed ID: 36898359
[TBL] [Abstract][Full Text] [Related]
18. [Urine metabolomics analysis based on ultra performance liquid chromatography-high resolution mass spectrometry combined with osmolality calibration sample concentration variability].
He Z; Lin H; Gui J; Zhu W; He J; Wang H; Feng L
Se Pu; 2021 Apr; 39(4):391-398. PubMed ID: 34227759
[TBL] [Abstract][Full Text] [Related]
19. Next-generation metabolic screening: targeted and untargeted metabolomics for the diagnosis of inborn errors of metabolism in individual patients.
Coene KLM; Kluijtmans LAJ; van der Heeft E; Engelke UFH; de Boer S; Hoegen B; Kwast HJT; van de Vorst M; Huigen MCDG; Keularts IMLW; Schreuder MF; van Karnebeek CDM; Wortmann SB; de Vries MC; Janssen MCH; Gilissen C; Engel J; Wevers RA
J Inherit Metab Dis; 2018 May; 41(3):337-353. PubMed ID: 29453510
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
